KFDA advises labeling change of salcatonin medicines

The Korea Food and Drug Administration said on Monday that it instructed 11 pharmaceutical companies producing salcatonin preparations to add the following statements to the package inserts of 14 salcatonin medicines: ‘withdrawal of Intranasal formulation for osteoporosis treatment’ and ‘restriction to indication for injectable use in Paget's disease.’

Among the relevant products are Miacal...